Antitussives Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Antitussives DMPK and Bioanalytical Services

Dextromethorphan occupies a unique position that no other compound in this library shares: it is simultaneously the drug to be analyzed and the analytical tool used to analyze others. Its O-demethylation to dextrorphan by CYP2D6 is the industry-standard reference reaction for CYP2D6 activity measurement. Every CYP2D6 inhibition screen — whether for antidepressants, beta-blockers, or antipsychotics — relies on dextromethorphan as the probe substrate. This dual identity means dextromethorphan workflows must distinguish two contexts: characterizing dextromethorphan’s own metabolism as a study object, and calibrating dextrorphan formation as a CYP2D6 DDI probe in co-incubated systems.

Creative Proteomics provides CYP2D6 probe-substrate-calibrated DDI screening, dextromethorphan metabolism and dextrorphan quantification, CYP2D6-genotyped incubation models, and custom probe-integrated DDI panel development.

Browse Drug Index Request Custom Method Support

Industry-Standard CYP2D6 ProbeDextromethorphan O-demethylation is the reference reaction for CYP2D6 activity — used in every CYP2D6 inhibition study across therapeutic classes.

Dual Identity: Drug + ToolDextromethorphan serves as both the study compound and the probe substrate measuring other compounds’ CYP2D6 inhibition liability.

CYP2D6 Genotype Affects Probe PerformanceProbe substrate conversion varies by CYP2D6 genotype — genotyped incubation models are required for calibrated DDI readouts.

CYP2D6 Probe Substrate Identity DMPK Strategy Map

⚡

The CYP2D6 Reference StandardDextromethorphan O-demethylation to dextrorphan is the most widely used CYP2D6 probe reaction — the benchmark against which CYP2D6 inhibition is measured.

🧬

CYP2D6 Substrate MetabolismAs a study compound, dextromethorphan Phase I metabolism requires CYP2D6-genotyped microsome/hepatocyte incubation and dextrorphan quantification.

📊

CYP2D6 Probe in DDI ScreeningAs a probe, dextrorphan formation rate in the presence/absence of a test compound quantifies test-compound CYP2D6 inhibition IC₅₀.

🔬

Calibrated Probe-Substrate DDI PanelsCYP2D6-genotyped probe incubation with kinetic parameter calibration across genotype groups for standardized inhibition readouts.

Dextromethorphan dual-identity workflow design.Creative Proteomics distinguishes the two contexts — dextromethorphan as study compound vs dextromethorphan as CYP2D6 probe — because the incubation conditions, internal standard strategy, and data interpretation differ between them.

Antitussive Drug Index

Find the Antitussive Compound Behind the Study

Dextromethorphan studies require a context distinction: is the compound the study object (its own CYP2D6 metabolism), or the DDI probe substrate (measuring CYP2D6 inhibition by another compound)? The analytical method changes depending on the answer. The drug panel is intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters.

1 entry · Page 1 of 1

Analytical Pain Points

What Drives Assay Failure in Dextromethorphan Studies?

Dextromethorphan assays fail when the dual identity — study compound vs DDI probe — is not explicitly defined before method development. A protocol designed for dextromethorphan metabolism quantification differs from one designed for CYP2D6 inhibition screening, even though both measure dextrorphan formation.

Study Compound vs Probe: Two Different Protocols

As a study compound, dextromethorphan needs metabolite profiling and kinetics. As a probe, it needs calibrated dextrorphan formation rates under controlled inhibitor exposure. One protocol does not serve both contexts.

Our responseContext-defined workflow selection: metabolite profiling for study-compound studies, probe-calibrated incubation for DDI screening.

CYP Inhibition Assays →

Dextrorphan Quantification Is the Common Readout

Whether studying dextromethorphan itself or using it as a probe, dextrorphan is the analytical endpoint. Internal standard strategy, calibration range, and matrix differ between the two contexts.

Our responseContext-specific dextrorphan quantification with matched internal standard selection and calibration range per study objective.

Phase I & II Metabolite Characterization →

CYP2D6 Genotype Determines Probe Baseline Activity

Dextromethorphan O-demethylation rate varies by CYP2D6 genotype. A probe calibration that works for extensive metabolizer microsomes overestimates inhibition in poor metabolizers and underestimates it in ultra-rapid metabolizers.

Our responseCYP2D6-genotyped probe incubation with genotype-stratified calibration across PM, EM, and UM donor models.

Metabolite Identification →

Co-Incubated Antidepressants Interfere with Probe Readout

When dextromethorphan is used as a probe alongside fluoxetine or paroxetine (CYP2D6 strong inhibitors), probe metabolism is suppressed to near-zero — producing data dominated by the co-incubated inhibitor, not the test compound under investigation.

Our responseSequential incubation protocols separating probe activity measurement from co-incubated inhibitor exposure to prevent probe-suppression artifacts.

Custom LC-MS/MS Method Development →

Probe-Integrated Multi-Compound DDI Panels

When dextromethorphan serves as the CYP2D6 probe in a multi-compound DDI panel, its own metabolism data must be separated from its probe readout data — two datasets from one compound in one incubation.

Our responseProbe-integrated panel design with separate data channels for dextromethorphan-as-substrate and dextromethorphan-as-probe readouts.

Custom Panels →

Focused Service Paths

Four Practical Routes for Dextromethorphan Studies

Dextromethorphan workflows should be selected according to context: CYP2D6 substrate metabolism and dextrorphan quantification for study-compound studies; probe-calibrated CYP2D6 inhibition screening for DDI studies; or probe-integrated panels where dextromethorphan serves both roles within one study design.

CYP2D6 Probe-Substrate DDI Screening

Dextromethorphan as CYP2D6 probe — calibrated dextrorphan formation in the presence/absence of test compounds for IC₅₀ determination.

CYP2D6-genotyped microsome incubation
Dextrorphan formation rate measurement
Test-compound CYP2D6 inhibition IC₅₀

CYP Inhibition Assays →

Dextromethorphan Metabolism & Dextrorphan Quantification

Dextromethorphan as study compound — CYP2D6 Phase I metabolism profiling with dextrorphan metabolite quantification.

CYP2D6 substrate depletion kinetics
Dextrorphan formation rate and metabolite ID
Genotyped incubation for variability assessment

Phase I & II Metabolite Characterization →

Genotype-Calibrated Probe Baseline Profiling

CYP2D6-genotyped probe substrate calibration across PM, EM, and UM donor models for standardized inhibition reporting.

Genotype-stratified dextrorphan baseline
PM / EM / UM donor microsome panels
Probe calibration before inhibitor exposure

Metabolite Identification →

Probe-Integrated Multi-Compound DDI Panel

Dextromethorphan as CYP2D6 probe within a multi-compound DDI panel — separate substrate and probe data channels from one incubation.

Dual-context data extraction
Probe-substrate signal separation
Panel-level probe calibration

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need CYP2D6 Probe or Dextromethorphan Support?

If your study uses dextromethorphan as a CYP2D6 probe, a study compound, or both — Creative Proteomics defines the context before building the analytical method.

Creative Proteomics determines whether dextromethorphan serves as the study object, the DDI probe, or both — then selects incubation conditions, CYP2D6 genotype models, internal standard strategy, and data interpretation accordingly.

Study compound or probe

CYP2D6 genotype model

Dextrorphan quantification

Co-incubated compounds

DDI inhibitor and IC₅₀ target

Panel requirements